Table 1.
Baseline characteristics of the MAPT analytical cohort (n = 712)
| Total | Omega-3 PUFA |
Serum 25-OH-D |
Plasma homocysteine |
||||
|---|---|---|---|---|---|---|---|
| Optimum (n = 524) | Suboptimum ≤4.82 wt% (n = 188) | Optimum (n = 390) | Suboptimum ≤20 ng/mL (n = 322) | Optimum (n = 292) | Suboptimum ≥14 μmol/L (n = 420) | ||
| Age, y; mean (SD)∗ | 75.6 (4.5) | 75.5 (4.5) | 76.1 (4.5) | 75.0 (4.2) | 76.3 (4.8) | 74.6 (4.0) | 76.3 (4.7) |
| Women, n (%) | 480 (67.4) | 356 (67.9) | 124 (66.0) | 266 (68.2) | 214 (66.5) | 231 (79.1) | 249 (59.3) |
| Education | |||||||
| No diploma/primary school | 168 (23.6) | 104 (19.9) | 64 (34.0) | 71 (18.2) | 97 (30.1) | 66 (22.6) | 102 (24.3) |
| Secondary education | 244 (34.3) | 184 (35.1) | 60 (31.9) | 148 (37.9) | 96 (29.8) | 98 (33.5) | 146 (34.8) |
| High-school diploma | 104 (14.6) | 82 (15.7) | 22 (11.7) | 52 (13.3) | 52 (16.1) | 48 (16.4) | 56 (13.3) |
| University level | 196 (27.5) | 154 (29.4) | 42 (22.3) | 119 (30.5) | 77 (23.9) | 80 (27.4) | 116 (27.6) |
| MMSE | 28.0 (1.6) | 28.1 (1.6) | 27.8 (1.8) | 28.1 (1.6) | 27.9 (1.7) | 27.9 (1.6) | 28.1 (1.6) |
| Cognitive Z score | −0.029 (0.70) | 0.015 (0.66) | −0.15 (0.78) | 0.049 (0.66) | −0.12 (0.73) | 0.07 (0.63) | −0.10 (0.74) |
| APOE ε4 available, n (%) | 624 (87.6) | 472 (90.1) | 152 (80.9) | 346 (88.7) | 278 (86.3) | 261 (89.4) | 363 (86.4) |
| APOE ε4 carrier, n (%) | 129 (20.7) | 97 (20.6) | 32 (21.1) | 74 (21.4) | 55 (19.8) | 50 (19.2) | 79 (21.8) |
| Treatment arm | |||||||
| O3 | 180 (25.3) | 126 (24.1) | 54 (28.9) | 96 (24.6) | 84 (26.1) | 67 (22.9) | 113 (26.9) |
| MDI | 176 (24.7) | 141 (26.9) | 34 (18.2) | 94 (24.1) | 82 (25.5) | 77 (26.4) | 99 (23.6) |
| O3 + MDI | 177 (24.9) | 126 (24.1) | 51 (27.3) | 100 (25.6) | 77 (23.9) | 71 (24.3) | 106 (25.2) |
| Placebo | 179 (25.1) | 131 (25.0) | 48 (25.7) | 100 (25.6) | 79 (24.5) | 77 (26.4) | 102 (24.3) |
| Omega-3 PUFA, wt% | 5.8 (1.5) | 6.4 (1.2) | 4.0 (0.6) | 5.9 (1.5) | 5.6 (1.4) | 6.2 (1.5) | 5.5 (1.4) |
| Serum 25-OH-D, ng/mL | 23.7 (12.3) | 24.1 (12.5) | 22.6 (11.7) | 31.7 (10.4) | 13.7 (4.3) | 24.0 (12.9) | 23.5 (11.8) |
| Plasma homocysteine, μmol/L | 15.8 (5.3) | 15.3 (5.3) | 17.1 (5.3) | 15.6 (5.0) | 16.0 (5.7) | 11.4 (1.7) | 18.8 (4.9) |
Abbreviations: MAPT, multidomain Alzheimer prevention trial; PUFA, polyunsaturated fatty acid; Serum 25-OH-D, serum 25-hydroxy vitamin D; SD, standard deviation; MMSE, Mini-Mental State Examination; APOE, apolipoprotein E; O3, omega-3 PUFA intervention; MDI, multidomain intervention.
∗
Mean (SD) or number (% of total).